Cargando…

Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease

Connective tissue diseases (CTDs) are an important secondary cause of interstitial lung disease (ILD). If a CTD is suspected, clinicians are recommended to perform autoantibody testing, including for myositis autoantibodies. In this study, the prevalence and clinical associations of novel myositis a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moll, Sofia A., Platenburg, Mark G. J. P., Platteel, Anouk C. M., Vorselaars, Adriane D. M., Janssen Bonàs, Montse, Roodenburg-Benschop, Claudia, Meek, Bob, van Moorsel, Coline H. M., Grutters, Jan C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563342/ https://www.ncbi.nlm.nih.gov/pubmed/32933078 http://dx.doi.org/10.3390/jcm9092944

Ejemplares similares

Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases
por: Moll, Sofia A., et al.
Publicado: (2022)

Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy
por: Vorselaars, Adriane D. M., et al.
Publicado: (2013)

Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects
por: Kraaijvanger, Raisa, et al.
Publicado: (2020)

Clustering of lung diseases in the family of interstitial lung disease patients
por: Terwiel, Michelle, et al.
Publicado: (2022)

Myositis interstitial lung disease and autoantibodies
por: Chaudhry, Shire, et al.
Publicado: (2023)

Non-specific and Usual Interstitial Pneumonia, Short-Term Survival After Surgical Biopsy
por: Knipscheer, Barbara J., et al.
Publicado: (2015)

Elevated Serum Amyloid a Levels Are not Specific for Sarcoidosis but Associate with a Fibrotic Pulmonary Phenotype
por: Beijer, Els, et al.
Publicado: (2021)

Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study
por: Kahlmann, Vivienne, et al.
Publicado: (2020)

Decreased Survival and Lung Function in Progressive Pulmonary Fibrosis
por: Platenburg, Mark G. J. P., et al.
Publicado: (2023)

Significance of Myositis Autoantibody in Patients with Idiopathic Interstitial Lung Disease
por: Song, Ju Sun, et al.
Publicado: (2015)

Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies
por: Lia, Yihua, et al.
Publicado: (2021)

Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane
por: Willemsen, Annelieke E. C. A. B., et al.
Publicado: (2019)

A Polymorphism in C-C Chemokine Receptor 5 (CCR5) Associates with Löfgren’s Syndrome and Alters Receptor Expression as well as Functional Response
por: Karakaya, Bekir, et al.
Publicado: (2021)

Understanding Idiopathic Interstitial Pneumonia: A Gene-Based Review of Stressed Lungs
por: van Moorsel, Coline H. M., et al.
Publicado: (2015)

Interstitial lung disease associated with inflammatory myositis: Autoantibodies, clinical phenotypes, and progressive fibrosis
por: Ceribelli, Angela, et al.
Publicado: (2023)

Myositis autoantibodies and clinical phenotypes
por: Ghirardello, Anna, et al.
Publicado: (2014)

Course of SP-D, YKL-40, CCL18 and CA 15-3 in adult patients hospitalised with community-acquired pneumonia and their association with disease severity and aetiology: A post-hoc analysis
por: Spoorenberg, Simone M. C., et al.
Publicado: (2018)

Analysis of myositis autoantibodies in Chinese patients with cancer‐associated myositis
por: Li, Liubing, et al.
Publicado: (2020)

Telomere shortening and DNA damage in culprit cells of different types of progressive fibrosing interstitial lung disease
por: van Batenburg, Aernoud A., et al.
Publicado: (2021)

Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis
por: Schimmelpennink, M. C., et al.
Publicado: (2022)

Myositis Specific Autoantibodies: A Clinical Perspective
por: Alenzi, Fahidah M
Publicado: (2020)

Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease
por: Mammen, Andrew L., et al.
Publicado: (2015)

Myositis-specific autoantibodies: detection and clinical associations
por: van Dooren, Sander H. J., et al.
Publicado: (2011)

Bench to bedside review of myositis autoantibodies
por: Palterer, Boaz, et al.
Publicado: (2018)

Genetic disorders of the surfactant system: focus on adult disease
por: van Moorsel, Coline H.M., et al.
Publicado: (2021)

Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort
por: Chen, Fang, et al.
Publicado: (2022)

Phenotypic Characterization of Human Intermediate Monocytes
por: Hijdra, Daniëlle, et al.
Publicado: (2013)

Prevalence of Myositis-Specific Autoantibodies and Myositis-Associated Autoantibodies in COVID-19 Patients: A Pilot Study and Literature Review
por: Swartzman, Isaac, et al.
Publicado: (2022)

Differential expression of TNFR1 (CD120a) and TNFR2 (CD120b) on subpopulations of human monocytes
por: Hijdra, Daniëlle, et al.
Publicado: (2012)

Telomerase Reverse Transcriptase Polymorphism rs2736100: A Balancing Act between Cancer and Non-Cancer Disease, a Meta-Analysis
por: Snetselaar, Reinier, et al.
Publicado: (2018)

The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity
por: Tansley, Sarah L, et al.
Publicado: (2020)

Clinical Usefulness of Autoantibodies in Idiopathic Inflammatory Myositis
por: García-De La Torre, Ignacio
Publicado: (2015)

Tropomyosin autoantibodies associated with checkpoint inhibitor myositis
por: Zaenker, Pauline, et al.
Publicado: (2020)

The Role of Myositis-Specific Autoantibodies in the Dermatomyositis Spectrum
por: Marasandra Ramesh, Harshita, et al.
Publicado: (2022)

The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies
por: Rider, Lisa G., et al.
Publicado: (2013)

Systematic review of drug effects in humans and models with surfactant-processing disease
por: Klay, Dymph, et al.
Publicado: (2018)

IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study
por: Korthagen, Nicoline M., et al.
Publicado: (2012)

The MUC5B Promoter Polymorphism Associates With Severe COVID-19 in the European Population
por: van Moorsel, Coline H. M., et al.
Publicado: (2021)

Novel autoantibodies and clinical phenotypes in adult and juvenile myositis
por: Betteridge, Zoe E, et al.
Publicado: (2011)

The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis
por: Tansley, Sarah L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r9dh9km8egeo0pold9tc8tbdvk